August 25, 2026
Popular weight loss drug linked to unexpected mental health benefits
Semaglutide use was linked to fewer hospital stays in people with bipolar disorder, but more testing is needed
BySanjana Gajbhiye
Editor
Medicines are usually made to treat one health problem, but they can sometimes have other effects too
Now, researchers are asking whether semaglutide could have unexpected benefits for people with bipolar disorder
The researchers found a lower risk of mental health hospitalization when people with bipolar disorder were taking semaglutide
Semaglutide is a medicine used to treat diabetes and obesity
Bipolar disorder can return in episodes severe enough to require hospital care. In Sweden, an average psychiatric stay for bipolar disorder lasts about 21 days, bringing major personal and financial costs
Rates of type 2 diabetes and obesity are roughly twice as high among people with bipolar disorder as they are in the wider population
GLP-1 medicines may affect the brain
Semaglutide belongs to a group called glucagon-like peptide 1 receptor agonists, usually shortened to GLP-1 medicines
These medicines work by activating GLP-1 receptors, which help cells respond to chemical signals
Other drugs in this group include liraglutide and dulaglutide
Because GLP-1 medicines may affect inflammation and stress inside brain cells, researchers have begun asking whether they could also influence mental health
A pattern emerges in the records
Professor Mark Taylor of the School of Medicine and Dentistry at Griffith University led the work using Sweden’s national health records
The analysis included 14,694 people who had bipolar disorder and used at least one diabetes medicine between 2009 and 2024
Among them, 5,200 people used a GLP-1 medicine, and 3,682 used semaglutide. Participants were followed for an average of six years
The team compared each person with themselves by looking at periods when they used a GLP-1 drug and periods when they did not
This method reduces the influence of personal traits that stay mostly the same, such as sex or illness severity at the beginning
The team also accounted for changes in other diabetes and mental health medicines
Semaglutide linked to fewer hospital stays
During the follow-up period, 5,288 people had at least one hospital stay for mental health care
Semaglutide use was linked to a 21 percent lower risk of such a stay than periods when the same people were not using a GLP-1 medicine
“People with bipolar disorder who were taking semaglutide (otherwise known as Ozempic or Wegovy), a type of GLP-1 medication, had significantly lower rates of psychiatric hospitalization compared with periods when they were not taking GLP-1 medicines,” Professor Taylor said
The team also examined hospital stays caused by a bipolar relapse, meaning a return of serious symptoms. During semaglutide use, the risk of this type of hospital stay was 17 percent lower
The result stayed similar when the researchers removed the first 30 days of treatment and non-treatment periods
This check reduced concern that doctors started or stopped the medicine because a person’s mental health was already changing
Other medicines gave mixed results
When all GLP-1 medicines were grouped together, use was linked to a 13 percent lower risk of any mental health hospital stay and a 15 percent lower risk of hospitalization for a bipolar relapse
However, liraglutide and dulaglutide did not show a clear link with fewer hospital stays when examined separately
Fewer people used these medicines, which made it harder to tell whether a real difference existed
The researchers found no clear link between GLP-1 medicines and sick leave lasting more than 14 days for mental health reasons
The possible benefit therefore did not appear across every outcome examined
The brain question remains
Why might a diabetes and obesity medicine be linked with fewer mental health hospital stays?
Weight loss and better physical health could indirectly support mental health, while semaglutide might also act more directly on the brain
Animal work discussed in the paper suggests that GLP-1 activity may reduce neuroinflammation, which is harmful immune activity in the brain. It may also reduce oxidative stress, a form of cell damage caused by unstable molecules
These effects could help nerve cells resist damage. However, the Swedish records did not measure inflammation, cell stress, or brain function, so they cannot show whether these processes explain the result
“The findings add to growing evidence that GLP-1 receptor agonists may have benefits beyond diabetes and obesity treatment, and could represent a promising new avenue for bipolar research,” Professor Taylor said
This possibility now needs a carefully controlled test
The results cannot prove cause
The researchers looked at treatment records that already existed
Because people were not randomly given different medicines, the results cannot prove that semaglutide caused fewer hospital stays
People may have taken semaglutide when their mental health was already more stable or when they were getting regular care
The researchers tried to account for this, but other differences may still have affected the results
Limitations of the study
The records lacked detailed information about mood symptoms, weight changes, body mass index (BMI), and long-term blood sugar levels
The researchers therefore could not tell whether changes in physical health helped explain the link
The work took place in Sweden, where healthcare is available with little personal cost
The results may not be the same in countries where cost, insurance, or access affects who can get GLP-1 medicines
The analysis also included the COVID-19 pandemic, which may have affected the results
Clinical trials come next
A randomized controlled trial would place people into treatment groups by chance and then follow what happens
This would provide stronger evidence about whether semaglutide itself lowers the risk of bipolar relapse or a hospital stay for mental health care
For now, the findings support further testing rather than a change in bipolar treatment. Semaglutide is not a proven mood medicine, and these results do not show that it should replace established care
For now, semaglutide’s link with fewer mental health hospital stays offers a promising lead, but clinical trials are needed to determine whether the drug itself is responsible
The study is published in the journal Acta Psychiatrica Scandinavica
Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates
Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com
—–
